2. Academic Validation
  3. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus

  • J Med Chem. 2010 Sep 9;53(17):6355-60. doi: 10.1021/jm100332n.
Sumihiro Nomura 1,  Shigeki Sakamaki,  Mitsuya Hongu,  Eiji Kawanishi,  Yuichi Koga,  Toshiaki Sakamoto,  Yasuo Yamamoto,  Kiichiro Ueta,  Hirotaka Kimata,  Keiko Nakayama,  Minoru Tsuda-Tsukimoto
Affiliations

Affiliation

  • 1 Medicinal Chemistry Research Laboratories, Mitsubishi Tanabe Pharma Corporation, 2-2-50 Kawagishi, Toda, Saitama, Japan. nomura.sumihiro@mw.mt-pharma.co.jp
PMID: 20690635 DOI: 10.1021/jm100332n
Abstract

We discovered that C-glucosides 4 bearing a heteroaromatic ring formed metabolically more stable inhibitors for sodium-dependent glucose cotransporter 2 (SGLT2) than the O-glucoside, 2 (T-1095). A novel thiophene derivative 4b-3 (canagliflozin) was a highly potent and selective SGLT2 Inhibitor and showed pronounced anti-hyperglycemic effects in high-fat diet fed KK (HF-KK) mice.

Figures